Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis

Calcitonin gene-related peptide (CGRP) inhibitors are a migraine prophylaxis treatment for patients who have not responded to conventional migraine therapies. However, it is unclear whether trying different CGRP inhibitors in patients who do not respond well to initial CGRP inhibitor treatment is effective or if it may lead to unnecessary exposure for patients and wasted health care resources.

The public drug plans’ reimbursement criteria for CGRP inhibitors do not exclude prior use of a different CGRP inhibitor, allowing for a switch after initial treatment failure. Evidence is needed to inform the policies regulating the use of CGRP inhibitors for migraine prophylaxis for patients who have received a previous CGRP inhibitor.

Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the Canada's Drug Agency website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.